MYRIAD GENETICS INC. - COMMON STOCK

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

31 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

26 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

28 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

19 Sep 2023 09:00:00 By Nasdaq GlobeNewswire

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

19 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

18 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

05 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk

22 Aug 2023 09:00:00 By Nasdaq GlobeNewswire

Myriad Genetics to Host Investor Day on September 19, 2023

17 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

15 Aug 2023 07:05:00 By Nasdaq GlobeNewswire

Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment

08 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

07 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth

03 Aug 2023 16:05:01 By Nasdaq GlobeNewswire

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

27 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces New $90 Million Asset-Based Credit Facility

06 Jul 2023 08:30:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

12 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

07 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

01 Jun 2023 08:00:01 By Nasdaq GlobeNewswire